Clinical Implications from the MAIA and SWOG S0777 Studies
A summary of updates from the MAIA and SWOG S0777 studies, with a focus on efficacy and tolerability data.
Video Player is loading.
EP: 1.Goals of Therapy and Treatment Options for Patients with Transplant-Ineligible NDMM
Now Viewing
EP: 2.Clinical Implications from the MAIA and SWOG S0777 Studies
EP: 3.Assessing and Supporting Frail Patients with NDMM
EP: 4.Implementing Real-world Evidence into Clinical Practice in NDMM
EP: 5.Optimizing Treatment Duration and Adverse Effect Management in Patients with NDMM
EP: 6.Addressing Unmet Needs and Disparities Across Patient Populations in Multiple Myeloma
EP: 7.Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma
Recent Videos
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights from ACRO 2025
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
Precision Active Surveillance: Leveraging Genomic Testing and CCR Scores in Prostate Cancer Management
Using Genetic Information to Guide Precision Medicine and Personalized Treatment in Prostate Cancer: Expert Perspectives on an Evolving Landscape
Prolaris and Beyond: How Genomic Testing Has Revolutionized Prostate Cancer Management and Treatment Decisions
Future of HER2-Directed Tumor-Agnostic Therapies
Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
HER2 Key Differences and Current Approaches to Biomarker Testing
Related Content
